Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible staphylococcus aureus bacteremia

Microbial Drug Resistance

Volumn 20, Issue 6, 2014, Pages 568-574

  Lee, Shinwon ^a   Kwon, Ki Tae ^b   Kim, Hye In ^c   Chang, Hyun Ha ^c   Lee, Jong Myung ^c   Choe, Pyoeng Gyun ^d   Park, Wan Beom ^d   Kim, Nam Joong ^d   Oh, Myoung Don ^d   Song, Do Young ^b   Kim, Shin Woo ^c  

^a Pusan National University School of Medicine   (South Korea)

^b Daegu Fatima Hospital   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFAZOLIN; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; METICILLIN;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL LOAD; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENDOCARDITIS; FEMALE; HUMAN; INFECTION; INOCULATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; RISK FACTOR; TREATMENT FAILURE; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CEFAZOLIN; FEMALE; HUMANS; MALE; METHICILLIN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84915823631     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2013.0229     Document Type: Article

References (33)

1. Aguado, J.M., R. San-Juan, A. Lalueza, F. Sanz, J. Rodriguez-Otero, C. Gomez-Gonzalez, and F. Chaves. 2011. High vancomycin MIC and complicated methicillinsusceptible Staphylococcus aureus bacteremia. Emerg. Infect. Dis. 17:1099-1102.
2. Baddour, L.M., W.R. Wilson, A.S. Bayer, V.G. Fowler, Jr., A.F. Bolger, M.E. Levison, P. Ferrieri, M.A. Gerber, L.Y. Tani, M.H. Gewitz, et al. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
3. Bryant, R.E., and R.H. Alford. 1977. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 237:569-570.
4. Chapman, S.W., and R.T. Steigbigel. 1983. Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. J. Infect. Dis. 147: 1078-1089.
5. Chia, J.W., L.Y. Hsu, L.Y. Chai, and P.A. Tambyah. 2008. Epidemiology and outcomes of community-onset methicillin-susceptible Staphylococcus aureus bacteraemia in a university hospital in Singapore. BMC Infect. Dis. 8:14.
6. Clinical and Laboratory Standards Institute. 2008. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Culver, D.H., T.C. Horan, R.P. Gaynes, W.J. Martone, W.R. Jarvis, T.G. Emori, S.N. Banerjee, J.R. Edwards, J.S. Tolson, T.S Henderson, et al. 1991. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am. J. Med. 91:152S-157S.
8. Fowler, Jr., V.G., W. Scheld, M. Bayer. 2010. Endocarditis and Intravascular infections. In G.L. Mandell (ed.), Principles and Practice of Infectious Diseases. 7th ed., Churchill Livingstone, Philadelphia, pp. 1067-1112.
9. Goldman, P.L., and R.G. Petersdorf. 1980. Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. 141:331-337.
10. Guillemot, D., S. Bonacorsi, J.S. Blanchard, P. Weber, S. Simon, B. Guesnon, E. Bingen, and C. Carbon. 2004. Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase. Antimicrob. Agents Chemother. 48:4618-4623.
11. Holmes, N.E., J.D. Turnidge, W.J. Munckhof, J.O. Robinson, T.M. Korman, M.V. O'Sullivan, T.L. Anderson, S.A. Roberts, W. Gao, K.J. Christiansen, et al. 2011. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347.
12. Holmes, N.E., J.D. Turnidge, W.J. Munckhof, J.O. Robinson, T.M. Korman, M.V. O'Sullivan, T.L. Anderson, S.A. Roberts, S.J. Warren, W. Gao, et al. 2013. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin. Microbiol. Infect. 19:1163-1168.
13. Kernodle D.S., P.A. McGraw, C.W. Stratton, and A.B. Kaiser. 1990. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants. Antimicrob. Agents Chemother. 34:420-425.
14. Kernodle, D.S., C.W. Stratton, L.W. McMurray, J.R. Chipley, and P.A. McGraw. 1989. Differentiation of betalactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J. Infect. Dis. 159:103-108.
15. Kim, S.H., K.H. Kim, H.B. Kim, N.J. Kim, E.C. Kim, M.D. Oh, and K.W. Choe. 2008. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 52:192-197.
16. Laupland, K.B., T. Ross, and D.B. Gregson. 2008. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J. Infect. Dis. 198:336-343.
17. Lee, S., P.G. Choe, K.H. Song, S.W. Park, H.B. Kim, N.J. Kim, E.C. Kim, W.B. Park, and M.D. Oh. 2011. Is cefazolin inferior to nafcillin for treatment of methicillinsusceptible Staphylococcus aureus bacteremia Antimicrob. Agents Chemother. 55:5122-5126.
18. Livorsi, D.J., E. Crispell, S.W. Satola, E.M. Burd, R. Jerris, Y.F. Wang, and M.M. Farley. 2012. Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 56: 4474-4477.
19. McCabe, W.R., and G.G. Jackson. 1965. Treatment of pyelonephritis: bacterial, drug and host factors in success or failure among 252 patients. N. Engl. J. Med. 272:0137-0144.
20. Mylotte, J.M., and A. Tayara. 2000. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin. Infect. Dis. 31:1170-1174.
21. Nannini, E.C., K.V. Singh, C.A. Arias, and B.E. Murray. 2013. In vivo effect of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillinsusceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin. Antimicrob. Agents Chemother. 57:4276-4281.
22. Nannini, E.C., K.V. Singh, and B.E. Murray. 2003. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis. 37:1194-1198.
23. Nannini, E.C., M.E. Stryjewski, K.V. Singh, A. Bourgogne, T.H. Rude, G.R. Corey, V.G. Fowler, Jr., and B.E. Murray. 2009. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob. Agents Chemother. 53:3437-3441.
24. Otto, M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228.
25. Quinn, E.L., D. Pohlod, T. Madhavan, K. Burch, E. Fisher, and F. Cox. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128 Suppl:S386-S389.
26. Richmond, M.H. 1975. Immunological techniques for studying beta-lactamases. Methods Enzymol. 43:86-100.
27. Rincon, S., J. Reyes, L.P. Carvajal, N. Rojas, F. Cortes, D. Panesso,M.Guzman, J. Zurita, J.A. Adachi, B.E.Murray, et al. 2013. Cefazolin high-inoculum effect in methicillinsusceptible Staphylococcus aureus from South American hospitals. J. Antimicrob. Chemother. 68:2773-2778.
28. Rosdahl, V.T. 1986. Penicillinase production in Staphylococcus aureus strains of clinical importance. Dan. Med. Bull. 33:175-184.
29. Samuelsen, O., H.H. Haukland, B.C. Kahl, C. von Eiff, R.A. Proctor, H. Ulvatne, K. Sandvik, and L.H. Vorland. 2005. Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J. Antimicrob. Chemother. 56:1126-1129.
30. van Hal, S.J., S.O. Jensen, V.L. Vaska, B.A. Espedido, D.L. Paterson, and I.B. Gosbell. 2012. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev. 25:362-386.
31. Voladri, R.K., and D.S. Kernodle. 1998. Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:3163-3168.
32. Voladri, R.K., M.K. Tummuru, and D.S. Kernodle. 1996. Structure-function relationships among wild-type variants of Staphylococcus aureus beta-lactamase: importance of amino acids 128 and 216. J. Bacteriol. 178:7248-7253.
33. Zygmunt, D.J., C.W. Stratton, and D.S. Kernodle. 1992. Characterization of four beta-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36: 440-445.